Arthritis Research & Therapy

Table 2 In vitro parameters of GC sensitivity and relative decrease in DAS

From: In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis

Bioassays			GC binding assay
	β (95% CI)^a	P value		β (95% CI)^a	P value
IL-2-EC₅₀	-0.014 (-0.028-0.001)	0.058	K_D	0.03 (0.014-0.046)	0.001
Age	0.005 (-0.002-0.110)	0.161	Age	0.009 (0.002-0.017)	0.020
Gender	0.128 (-0.057-0.312)	0.169	Gender	0.199 (0.013-0.385)	0.037
Use of NSAID	0.087 (-0.087-0.261)	0.316	Use of NSAID	0.212 (0.025-0.400)	0.028
Number of DMARDs	0.023 (-0.079-0.125)	0.647	Number of DMARDs	0.112 (0.004-0.221)	0.043
Use of anti-TNF-α	0.008 (-0.283-0.299)	0.955	Use of anti-TNF-α	0.222 (-0.010-0.455)	0.060
GILZ-EC₅₀	-0.023 (-0.046-0.001)	0.062	GR number/1,000	0.027 (0.012-0.042)	0.001
Age	0.006 (-0.001-0.014)	0.079	Age	0.010 (0.002-0.018)	0.015
Gender	0.116 (-0.075-0.308)	0.225	Gender	0.017 (-0.188-0.223)	0.862
Use of NSAID	0.181 (-0.004-0.366)	0.055	Use of NSAID	0.203 (0.006-0.400)	0.044
Number of DMARDs	0.021 (-0.085-0.126)	0.695	Number of DMARDs	0.084 (-0.027-0.195)	0.132
Use of anti-TNF-α	0.023 (-0.270-0.320)	0.874	Use of anti-TNF-α	0.129 (-0.121-0.378)	0.297

In all four models, relative decrease in DAS was the dependent variable. The data represent the combined bioassays from intramuscularly treated patients with early (n = 14) and established RA (n = 31). GILZ-EC₅₀ and IL-2-EC₅₀ were not associated with relative decrease in DAS in orally treated patients in recent-onset RA (n = 22). The GC-binding assay is performed only in established RA (n = 30, all intramuscular GC). ^aValues represent adjusted β-coefficients and 95% confidence intervals.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com